Holen Sie sich die Stockscreener-App
0.9896
1.31%
0.0128
Schlusskurs vom Vortag:
$0.9768
Offen:
$0.9863
24-Stunden-Volumen:
384.92K
Relative Volume:
0.40
Marktkapitalisierung:
$105.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.31M
KGV:
-3.7414
EPS:
-0.2645
Netto-Cashflow:
$-21.07M
1W Leistung:
+9.17%
1M Leistung:
-7.51%
6M Leistung:
+131.76%
1J Leistung:
+15.20%
1-Tages-Spanne:
$0.9601
$0.997
1-Wochen-Bereich:
$0.90
$1.01
52-Wochen-Spanne:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Firmenname
Oncolytics Biotech Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ONCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.9896 | 103.68M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Eingeleitet | Lake Street | Buy |
| 2022-10-06 | Eingeleitet | Maxim Group | Buy |
| 2021-02-17 | Eingeleitet | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Aktie (ONCY) Neueste Nachrichten
Trend Tracker for (ONC) (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech reschedules shareholder vote on U.S. domicile move By Investing.com - Investing.com Nigeria
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada - pharmiweb.com
Oncolytics Biotech Plans Jurisdiction Shift to Nevada - TipRanks
Oncolytics Biotech Reschedules Special Meeting Of Shareholders To Change Jurisdiction Of Incorporation To Nevada - TradingView
Published on: 2025-12-08 13:44:04 - BỘ NỘI VỤ
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality - The Manila Times
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality - GlobeNewswire Inc.
Oncolytics to test immunotherapy against aggressive pancreatic cancer - Rare Cancer News
Is Oncolytics Biotech Inc. stock dividend yield sustainableMarket Volume Summary & Low Risk Profit Maximizing Plans - Newser
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - sharewise.com
Is Oncolytics Biotech Inc. stock undervalued vs historical averages2025 Historical Comparison & Weekly Watchlist for Hot Stocks - Newser
The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality - The Globe and Mail
ONCY: Virtual Meeting Scheduled for December 8 - GuruFocus
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is Oncolytics Biotech Inc. stock a buy for dividend growthJuly 2025 Trade Ideas & Safe Swing Trade Setups - moha.gov.vn
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential (PR Newswire) - Aktiellt
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep - Aktiellt
Oncolytics Biotech Reports Q3 2025 Financial Results - TipRanks
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types (PR Newswire) - Aktiellt
This Canadian biotech stock is tackling pancreatic Cancer - Cantech Letter
Are Analysts Too Optimistic About Nagreeka Capital Infrastructure Ltds Revenue GrowthGap Up/Gap Down Analysis & Achieve Consistent Profits - earlytimes.in
Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital - The Globe and Mail
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy - MSN
Can Oncolytics Biotech Inc. stock sustain free cash flow growthJuly 2025 Sector Moves & Real-Time Volume Surge Alerts - newser.com
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders - BioSpace
Can Oncolytics Biotech Inc. stock attract ESG capital inflowsJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
Oncolytics Biotech Reschedules Shareholder Meeting Amid SEC Delays - The Globe and Mail
Identifying reversal signals in Oncolytics Biotech Inc.Quarterly Profit Report & AI Powered Market Entry Ideas - newser.com
Oncolytics Biotech reschedules special meeting due to government shutdown By Investing.com - Investing.com Nigeria
Oncolytics Biotech reschedules special meeting due to government shutdown - Investing.com India
Oncolytics Biotech to launch pivotal pancreatic cancer trial in 2026 By Investing.com - Investing.com Australia
FY2025 EPS Estimate for Oncolytics Biotech Lifted by Analyst - MarketBeat
Oncolytics Biotech (TSX:ONC) Growth In Emerging Global Oncology Markets - Kalkine Media
Oncolytics Biotech (TSE:ONC) Advances Clinical Focus in Cancer Therapy - Kalkine Media
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer - BioSpace
Can Oncolytics Biotech Inc. stock rebound after recent weaknessDollar Strength & Long-Term Growth Portfolio Plans - newser.com
What recovery options are there for Oncolytics Biotech Inc.Quarterly Trade Report & Expert Approved Momentum Ideas - newser.com
Will Oncolytics Biotech Inc. outperform the marketWeekly Stock Summary & Community Consensus Stock Picks - newser.com
Using data tools to time your Oncolytics Biotech Inc. exitTreasury Yields & Low Drawdown Trading Techniques - newser.com
Backtesting results for Oncolytics Biotech Inc. trading strategies2025 Technical Patterns & Precise Buy Zone Identification - newser.com
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics Biotech (ONCY) Advances with FDA-Approved Study Desig - GuruFocus
Oncolytics Biotech Reaches FDA Alignment on Phase 3 Pancreatic Cancer Trial Design - marketscreener.com
Oncolytics Biotech to launch pivotal pancreatic cancer trial in 2026 - Investing.com India
Oncolytics, FDA agree on phase 3 trial design for elareorep in pancreatic cancer - Seeking Alpha
Oncolytics Biotech Inc. Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer - MarketScreener
Oncolytics Biotech rises as US FDA clears path for pancreatic cancer trial - TradingView
Oncolytics (ONCY) and FDA Align on Phase 3 Pelareorep Study Desi - GuruFocus
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - GlobeNewswire
Oncolytics Biotech rises as U.S. FDA clears path for pancreatic cancer trial - TradingView
Finanzdaten der Oncolytics Biotech Inc-Aktie (ONCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):